0001720725-22-000004.txt : 20220113 0001720725-22-000004.hdr.sgml : 20220113 20220113172005 ACCESSION NUMBER: 0001720725-22-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220109 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220113 DATE AS OF CHANGE: 20220113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 22529801 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 8-K 1 oyst-20220109.htm 8-K oyst-20220109
FALSE000172072500017207252022-01-132022-01-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
January 9, 2022
 
Oyster Point Pharma, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware 
001-39112
 81-1030955
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 (IRS Employer Identification No.)
202 Carnegie Center, Suite 109
Princeton, New Jersey 08540
(Address, including zip code, of Registrant’s principal executive offices)
(609382-9032
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, par value $0.001 per share OYST The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers.
On January 9, 2022, in addition to the approval of certain other compensatory arrangements, the compensation committee of the board of directors of Oyster Point Pharma, Inc. (the “Company”) approved the following performance units (“PSUs”) for certain Company employees, including the following executive officers:

NameTarget PSU Award
Jeffrey Nau, Chief Executive Officer170,600
Daniel Lochner, Chief Financial Officer80,000
John Snisarenko, Chief Commercial Officer45,000

These PSUs were granted pursuant to the Company’s 2019 Equity Incentive Plan. Upon vesting, each PSU will entitle the grantee to receive one share of the Company’s common stock. Shares issuable in respect of each PSU shall be eligible to vest, in an amount ranging from 0% to 125% of the target number PSU awards, on July 1, 2024, based on the achievement of one or more of three performance objectives related to the Company’s total prescriptions, net product revenue and total shareholder return achieved in the period beginning on January 1, 2022 and ending on June 30, 2023 (the “Performance Period”), respectively, based on the following performance milestones and the executive officer’s continued service with the Company:

25% to 50% of the target number of PSUs will vest based on the achievement of a milestone related to total prescriptions of TYRVAYA™ during the Performance Period (the “TRx Performance Objective”). To the extent the TRx Performance Objective is achieved between the milestone levels for 25% or 50% vesting of the target number of PSUs, the number of PSUs that will vest will be determined using linear interpolation;

25% to 50% of the target number of PSUs will vest based on the achievement of a milestone related to net product revenue of the Company during the Performance Period (the “Net Product Revenue Performance Objective”). To the extent the Net Product Revenue Performance Objective is achieved between the milestone levels for 25% or 50% vesting of the target number of PSUs, the number of PSUs that will vest will be determined using linear interpolation;

An additional 25% of the target number of PSUs will vest based on the achievement of a milestone related to the Company’s total shareholder return over the Performance Period (the “TSR Performance Objective”). The TSR Performance Objective will only be achievable if at least one of the TRx Performance Objective or Net Product Revenue Performance Objective is also achieved.

The foregoing summary of the PSUs is not intended to be complete and is qualified in its entirety by reference to the full text of the PSU forms of grant agreement to be filed as exhibits to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OYSTER POINT PHARMA, INC.
Date: January 13, 2022By:/s/ Jeffrey Nau
Jeffrey Nau, Ph.D., M.M.S.
President, Chief Executive Officer and Director


EX-101.SCH 2 oyst-20220109.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 oyst-20220109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Ex Transition Period Entity Ex Transition Period Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 4 oyst-20220109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 13, 2022
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name Oyster Point Pharma, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39112
Entity Tax Identification Number 81-1030955
Entity Address, Address Line One 202 Carnegie Center, Suite 109
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code (609
Local Phone Number 382-9032
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol OYST
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Amendment Flag false
Entity Central Index Key 0001720725
Document Period End Date Jan. 09, 2022
XML 6 oyst-20220109_htm.xml IDEA: XBRL DOCUMENT 0001720725 2022-01-13 2022-01-13 false 0001720725 8-K 2022-01-09 Oyster Point Pharma, Inc. DE 001-39112 81-1030955 202 Carnegie Center, Suite 109 Princeton NJ 08540 (609 382-9032 false false false false Common Stock, par value $0.001 per share OYST NASDAQ true true EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.oysterpointrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports oyst-20220109.htm oyst-20220109.xsd oyst-20220109_lab.xml oyst-20220109_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "oyst-20220109.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "oyst-20220109.htm" ] }, "labelLink": { "local": [ "oyst-20220109_lab.xml" ] }, "presentationLink": { "local": [ "oyst-20220109_pre.xml" ] }, "schema": { "local": [ "oyst-20220109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "oyst", "nsuri": "http://www.oysterpointrx.com/20220109", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20220109.htm", "contextRef": "iafd0e566d5b24d878e305146e04105b7_D20220113-20220113", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.oysterpointrx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20220109.htm", "contextRef": "iafd0e566d5b24d878e305146e04105b7_D20220113-20220113", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001720725-22-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001720725-22-000004-xbrl.zip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end